12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Empagliflozin: Additional Phase IIb data

Pooled data from 457 evaluable Type II diabetics enrolled in a pair of double-blind Phase IIb trials showed that once-daily 10 and 25 mg empagliflozin significantly reduced mean systolic blood pressure (SBP) from baseline to week 12 vs. placebo (3.8 and 4.5 mmHg, respectively, vs. 1.2 mmHg, p<0.05). Both doses of empagliflozin non-significantly reduced mean diastolic blood pressure (DBP) vs. placebo (2.3 and 2.7 mmHg, respectively, vs. 1.8 mmHg). In a subgroup of patients with a SBP of >140 mmHg at...

Read the full 382 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >